The March 6, 2012, Journal of Neurosurgery, published a PRADAXA CASE REPORT by three physicians raising concerns of PRADAXA CASES and potential fatalities. The PRADAXA CASE REPORT was entitled “Neurosurgical Complications of Direct Thrombin Inhibitors – Catastrophic Hemorrhage After Mild Traumatic Brain Injury in a Patient Receiving PRADAXA (DABIGATRAN)”. The physician authors were identified as Members of the Department of Neurosurgery, University of Utah, Salt Lake City, Utah, as follows: Sarah T. Garber, M.D., Walavan Sivakumar, M.D., and Richard H. Schmidt, M.D., Ph. D.. The PRADAXA CASE REPORT provided details on the fall of an elderly patient that was described as a “ground-level fall”. The patient was taking PRADAXA (DABIGATRAN EXTILATE) for atrial fibrillation or AFib. This is a medical condition that can lead to blood clots or resulting strokes and requires the use of a blood thinner. BOEHRINGER INGELHEIM is the manufacturer of PRADAXA (DABIGATRAN EXTILATE). The anatomical depiction below is from the BOEHRINGER INGELHEIM Annual Report that celebrates the use of PRADAXA (DABIGATRAN EXTILATE) to avoid life threatening conditions in patients with AFib or atrial fibrillation.
The PRADAXA CASE REPORT identifies the Utah patient as presenting with an expanding brain bleed, intracranial hemorrhaging, that led to his death within hours of admission. The authors expressed concern over the fact that candidates for PRADAXA (DABIGATRAN EXTILATE) are prone to falling given their age and other ailments. As a result, PRADAXA BLEEDS, or bleeding, from minor trauma could occur with greater frequency and present life threatening situations, or the potential for fatalities. The noted that “[t]here is currently no effective antidote to reverse the anticoagulant effect” of PRADAXA (DABIGATRAN EXTILATE) in the event of an emergency. This concerned them, as a group, because they anticipate neurosurgeons would be faced with similar clinical scenarios of unstoppable bleeding in patients that had taken PRADAXA (DABIGATRAN EXTILATE). While bleeding is a known risk of blood thinners, older blood thinners have a long standing history or use and “known” antidotes or reversal agents. Whether additional PRADAXA CASES involving death will be avoided as a result of this PRADAXA CASE REPORT remains to be determined.
PRADAXA CASES are being investigated by the sponsor of this site, Gabriel F. Zambrano, P.A.. FREE CASE EVALUATIONS are available upon request through use of the contact form below.
#PRADAXA #DABIGATRAN #PRADAXACASES #PRADAXALAWSUITS #PRADAXABLEEDS
#PRADAXABLOOD #PRADAXARECALL #FDA #PHARMA #BLOOD #BOEHRINGER #BI #BOEHRINGERINGELHEIM